[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CL2018001946A1 - Virus atenuados de bronquitis infecciosa. - Google Patents

Virus atenuados de bronquitis infecciosa.

Info

Publication number
CL2018001946A1
CL2018001946A1 CL2018001946A CL2018001946A CL2018001946A1 CL 2018001946 A1 CL2018001946 A1 CL 2018001946A1 CL 2018001946 A CL2018001946 A CL 2018001946A CL 2018001946 A CL2018001946 A CL 2018001946A CL 2018001946 A1 CL2018001946 A1 CL 2018001946A1
Authority
CL
Chile
Prior art keywords
infectious bronchitis
attenuated viruses
coronavirus
attenated
vaccine
Prior art date
Application number
CL2018001946A
Other languages
English (en)
Inventor
Erica Bickerton
Sarah Keep
Paul Britton
Original Assignee
The Pirbright Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Pirbright Inst filed Critical The Pirbright Inst
Publication of CL2018001946A1 publication Critical patent/CL2018001946A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20061—Methods of inactivation or attenuation
    • C12N2770/20062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA UN CORONAVIRUS ATENUADO VIVO QUE COMPRENDE UNA MUTACIÓN EN LA PROTEÍNA ESTRUCTURAL NSP-3 Y/O ELIMINACIÓN DE PROTEÍNAS ACCESORIAS 3A Y 3B. EL CORONAVIRUS SE PUEDE USAR COMO UNA VACUNA PARA TRATAR Y/O PREVENIR UNA ENFERMEDAD, TAL COMO BRONQUITIS INFECCIOSA, EN UN PACIENTE.
CL2018001946A 2016-01-27 2018-07-18 Virus atenuados de bronquitis infecciosa. CL2018001946A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1601498.7A GB201601498D0 (en) 2016-01-27 2016-01-27 Coronavirus

Publications (1)

Publication Number Publication Date
CL2018001946A1 true CL2018001946A1 (es) 2019-02-15

Family

ID=55535017

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001946A CL2018001946A1 (es) 2016-01-27 2018-07-18 Virus atenuados de bronquitis infecciosa.

Country Status (17)

Country Link
US (1) US11202825B2 (es)
EP (1) EP3408381B1 (es)
JP (1) JP2019503693A (es)
KR (1) KR20180104088A (es)
CN (1) CN108884447B (es)
AU (1) AU2017211507B2 (es)
BR (1) BR112018015453A2 (es)
CA (1) CA3012024A1 (es)
CL (1) CL2018001946A1 (es)
GB (1) GB201601498D0 (es)
IL (1) IL259655A (es)
MX (1) MX2018009008A (es)
PE (1) PE20190121A1 (es)
PH (1) PH12018501154A1 (es)
RU (1) RU2018130683A (es)
WO (1) WO2017129975A1 (es)
ZA (1) ZA201803700B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110592031B (zh) * 2019-09-25 2023-03-14 华南农业大学 一株S蛋白融合HiBiT的传染性支气管炎重组病毒及制备方法与应用
CN111437384A (zh) * 2020-04-07 2020-07-24 四川骋誉生物制品有限公司 用于预防covid-19的蝙蝠源性冠状病毒疫苗
BR102020019867A2 (pt) * 2020-09-28 2022-04-12 Fundacao Univ Estadual Do Ceara Funece Uso da vacina de coronavírus aviário (ibv) como modelo de imunização em mamíferos contra sars-cov 2
JP2024004496A (ja) * 2020-10-14 2024-01-17 一般財団法人阪大微生物病研究会 ノックアウトコロナウイルス
CN113308440B (zh) * 2021-05-26 2023-04-28 武汉大学 一种n7-甲基转移酶缺陷型冠状病毒减毒疫苗株及其制备方法与应用
CN114807061A (zh) * 2021-12-22 2022-07-29 华南农业大学 鸡传染性支气管炎标记疫苗毒株及其制备方法、疫苗

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037650A (en) 1988-03-08 1991-08-06 Akzo N.V. Live combination vaccine
EP1073759B1 (en) 1998-05-01 2011-06-01 Schering-Plough Ltd. Recombinant virus expressing foreign dna encoding feline cd80, feline cd28, feline ctla-4 or feline cd86 and uses thereof
BR0209837A (pt) * 2001-05-17 2004-12-14 Univ Utrecht Partìcula semelhante a vìrus isolada ou recombimante capaz de replicação, composição, e, método para inibir ou bloquear uma infecção com um coronavìrus ou partìcula semelhante a coronavìrus
SI1610817T1 (sl) 2003-03-03 2010-01-29 Intervet Int Bv Virus infekcijskega bronhitisa s spremenjenim spike genom
RU2253870C1 (ru) 2004-04-26 2005-06-10 Общество с ограниченной ответственностью Научно-производственное объединение "Диагностические системы" РЕКОМБИНАНТНЫЕ БЕЛКИ, СОДЕРЖАЩИЕ ДИАГНОСТИЧЕСКИ ЗНАЧИМЫЕ АНТИГЕННЫЕ ЭПИТОПЫ БЕЛКОВ КОРОНАВИРУСА (SARS-CoV), СВЯЗАННОГО С ТЯЖЕЛЫМ ОСТРЫМ РЕСПИРАТОРНЫМ СИНДРОМОМ, И ПОСЛЕДОВАТЕЛЬНОСТИ СИНТЕТИЧЕСКИХ ГЕНОВ, КОДИРУЮЩИХ ДИАГНОСТИЧЕСКИ ЗНАЧИМЫЕ АНТИГЕННЫЕ ДЕТЕРМИНАНТЫ БЕЛКОВ КОРОНАВИРУСА (SARS-CoV), СВЯЗАННОГО С ТЯЖЕЛЫМ ОСТРЫМ РЕСПИРАТОРНЫМ СИНДРОМОМ
KR100902510B1 (ko) * 2007-08-27 2009-06-15 삼성전자주식회사 한 개의 스위칭 소자와 한 개의 저항체를 포함하는비휘발성 메모리 장치
GB0911794D0 (en) 2009-07-07 2009-08-19 Animal Health Inst Chimaeric protein

Also Published As

Publication number Publication date
PE20190121A1 (es) 2019-01-17
US20190022214A1 (en) 2019-01-24
KR20180104088A (ko) 2018-09-19
JP2019503693A (ja) 2019-02-14
ZA201803700B (en) 2022-12-21
CN108884447B (zh) 2022-07-26
RU2018130683A (ru) 2020-02-27
EP3408381B1 (en) 2021-06-23
US11202825B2 (en) 2021-12-21
MX2018009008A (es) 2018-11-19
CA3012024A1 (en) 2017-08-03
WO2017129975A1 (en) 2017-08-03
AU2017211507B2 (en) 2022-09-29
GB201601498D0 (en) 2016-03-09
RU2018130683A3 (es) 2020-04-21
CN108884447A (zh) 2018-11-23
IL259655A (en) 2018-07-31
PH12018501154A1 (en) 2019-01-28
BR112018015453A2 (pt) 2018-12-18
AU2017211507A1 (en) 2018-06-28
EP3408381A1 (en) 2018-12-05

Similar Documents

Publication Publication Date Title
CL2018001946A1 (es) Virus atenuados de bronquitis infecciosa.
MX2018014573A (es) Vacuna contra el virus del zika.
CL2019001433A1 (es) Moduladores de la proteína core de la hepatitis b. (divisional solicitud 201800684)
CL2017002230A1 (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la cápsida del vhb.
MX2016016722A (es) Coronavirus.
CO2017004290A2 (es) Composiciones y métodos para el silenciamiento de la expresión génica del virus de la hepatitis b
CR20160520A (es) Oligómeros y conjugados de oligómeros
CO2017006580A2 (es) Anticuerpos humanos para hemaglutinina de influenza
PH12017550022A1 (en) Phosphoramidates for the treatment of hepatitis b virus
CL2019000732A1 (es) Tratamiento avv de la enfermedad de huntington.
JO3573B1 (ar) تركيبات iRNA لفيروس الكبد (HBV) B وطرق لاستخدامها
GT201500020A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
EA201690556A1 (ru) Способы и фармацевтические композиции для лечения вызванных вирусом гепатита в инфекций
BR112018009009A2 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
EA201890454A1 (ru) Пирролопиримидиновые нуклеозиды и их аналоги, которые можно использовать в качестве противовирусных средств
EA201591761A1 (ru) Композиции на основе наночастиц
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
BR112018071048A2 (pt) combinações e métodos que compreendem um inibidor da montagem de capsídeos
CO2019009215A2 (es) Sal hemi-sulfato de nucleótido para el tratamiento del virus de la hepatitis c
DOP2016000336A (es) Derivados de isoindolina para uso en el tratamiento de una infeccion viral
BR112018069974A2 (pt) compostos de tiazolida para o tratamento de infecções virais
EA201790565A1 (ru) Композиции и способы для лечения предраковых поражений кожи
CU24580B1 (es) Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas
AR101814A1 (es) Partícula de tipo virus flavivirus
MX2018016306A (es) Virus de enteritis de pato y usos del mismo.